This inventor holds 2 USPTO granted patents. Top assignees: Cyclacel Limited, University of Dundee. Active years: 2003-2006.
Company Filing History:
Years Active: 2003-2006
Title: Robin Fahraeus: Innovator in Therapeutic Peptides
Introduction
Robin Fahraeus is a notable inventor based in Dundee, GB. He has made significant contributions to the field of therapeutic peptides, holding 2 patents that focus on innovative methods for inducing programmed cell death and tumor suppression.
Latest Patents
Fahraeus's latest patents include a therapeutic method that involves the use of peptides comprising a specific amino acid sequence. This method aims to induce programmed cell death in recipients. His second patent identifies substances that bind to cyclin-dependent kinases (cdk), which are crucial in tumor suppression. These substances can inhibit the phosphorylation of Rb protein, making them valuable in treating hyperproliferative disorders.
Career Highlights
Throughout his career, Robin Fahraeus has worked with prominent organizations such as Cyclacel Limited and the University of Dundee. His work has focused on the development of therapeutic strategies that leverage the properties of peptides to combat various diseases.
Collaborations
Fahraeus has collaborated with esteemed colleagues, including David Philip Lane and Christopher Gregory Proud. These partnerships have contributed to the advancement of research in the field of peptide therapeutics.
Conclusion
Robin Fahraeus is a distinguished inventor whose work in therapeutic peptides has the potential to impact medical treatments significantly. His innovative approaches and collaborations highlight the importance of research in developing effective therapies.